Glipizide and Synribo drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Glipizide (glipizide) and Synribo (omacetaxine mepesuccinate). Common drug interactions include diarrhoea among females and epistaxis among males.

The phase IV clinical study analyzes what interactions people have when they take Glipizide and Synribo. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Glipizide?

Glipizide has active ingredients of glipizide. It is often used in diabetes. eHealthMe is studying from 64,852 Glipizide users. Check the latest studies of Glipizide.

What is Synribo?

Synribo has active ingredients of omacetaxine mepesuccinate. eHealthMe is studying from 799 Synribo users. Check the latest studies of Synribo.

On Jul, 27, 2026

17 people who take Glipizide and Synribo together, and have interactions are studied.

Glipizide and Synribo drug interactions.

What are the common drug interactions of Glipizide and Synribo, by gender? *:

female:

Diarrhoea
Nausea (feeling of having an urge to vomit)
Platelet count decreased
White blood cell count decreased
Alopecia (absence of hair from areas of the body)
Haemoglobin decreased
Injection site erythema (redness at injection site)
Blindness transient (sudden loss of vision)
Cerebral arteritis (inflammation of the blood vessel of brain)
Dyspepsia (indigestion)

male:

Epistaxis (bleed from the nose)
Nausea (feeling of having an urge to vomit)
Back pain
Chest pain
Death
Eye pain
Localised infection (infection at the single location)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Platelet count decreased
White blood cell count decreased

What are the common drug interactions of Glipizide and Synribo, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Diarrhoea
Dyspepsia (indigestion)
Myalgia (muscle pain)
Nausea (feeling of having an urge to vomit)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Pain

60+:

Platelet count decreased
White blood cell count decreased
Blindness transient (sudden loss of vision)
Cerebral arteritis (inflammation of the blood vessel of brain)
Chest pain
Eye pain
Localised infection (infection at the single location)
Oedema (fluid collection in tissue)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Red blood cell count decreased

What are the existing conditions these people have? *

Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 17 people, 100.00%
Neuropathy Peripheral (surface nerve damage): 2 people, 11.76%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 11.76%
High Blood Pressure: 2 people, 11.76%
Multiple Myeloma (cancer of the plasma cells): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Glipizide and Synribo?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously